The role of CD26/DPP IV in chemokine processing

Chemical Immunology

Volumn 72, Issue , 1999, Pages 42-56

  Van Damme, Jo ^a   Struyf, Sofie ^a   Wuyts, Anja ^a   Van Coillie, Els ^a   Menten, Patricia ^a   Schols, Dominique ^a   Sozzani, Silvano ^b   De Meester, Ingrid ^c   Proost, Paul ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; DIPEPTIDYL PEPTIDASE IV; LYMPHOCYTE ANTIGEN;

ARTICLE; CHEMOTAXIS; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; MEMORY CELL; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN PURIFICATION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD26; CHEMOKINE CCL2; CHEMOKINES; CHEMOKINES, CC; CHEMOKINES, CXC; CHEMOTAXIS; HIV-1; HUMANS; RANTES;

EID: 0032809398     PISSN: 10150145     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Von Bonin A, Hühn J, Fleischer B: Dipeptidyl-peptidase IV/CD26 on T cells: Analysis of an alternative T-cell activation pathway. Immunol Rev 1998;161:43-53.
2. Morimoto C, Schlossman SF: The structure and function of CD26 in the T-cell immune response. Immunol Rev 1998;161:55-70.
3. Vanhoof G, Goossens F, De Meester I, Hendriks D, Scharpé S: Proline motifs in peptides and their biological processing. FASEB J 1995;9:736-744.
4. De Meester I, Korom S, Van Damme J, Scharpé S: CD26, let it cut or cut it down. Immunol. Today 1999, in press.
5. Van Damme J, Van Beeumen J, Conings R, Decock B, Billiau A: Purification of granulocyte chemotactic peptide/interleukin-8 reveals N-terminal sequence heterogeneity similar to that of p-thromboglobulin. Eur J Biochem 1989;181:337-344.
6. Wuyts A, Proost P, Van Damme J: Interleukin-8 and other CXC chemokines; in Thomson A (ed): The Cytokinc Handbook. London, Academic Press, 1998, chap 10, pp 271-311.
7. Walz A, Baggiolini M: Generation of the neutrophil-activating peptide NAP-2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases. J Exp Med 1990;171:449-454.
8. Proost P, Wuyts A, Conings R, Lenaerts JP, Billiau A, Opdenakker G, Van Damme J: Human and bovine granulocyte chemotactic protein-2: Complete amino acid sequence and functional characterization as chemokines. Biochemistry 1993;32:10170-10177.
9. Gong JH, dark-Lewis I: Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH,-terminal residues. J Exp Med 1995;181:631-640.
10. Proost P, Struyf S, Couvreur M, Lenaerts JP, Conings R, Menten P, Verhaert P, Wuyts A, Van Damme J: Posttranslational modifications affect the activity of the human monocyte chemotactic proteins MCP-1 and MCP-2: Identification of MCP-2(6-76) as a natural chemokine inhibitor. J Immunol 1998;160:4034-4041.
11. Opdenakker G, Rudd PM, Wormald M, Dwek RA, Van Damme J: Cells regulate the activities of cytokines by glycosylation. FASEB J 1995;9:453-457.
12. Liu ZG, Haelens A, Wuyts A, Struyf S, Pang XW, Proost P, Chen WF, Van Damme J: Isolation of a lymphocyte chemotactic factor produced by the murine thymic epithelial cell line MTEC1: Identification as a 30 kDa glycosylated form of MCP-1. Eur Cytokine Netw 1996;7:381-388.
13. Wuyts A, Haelens A, Proost P, Lenaerts JP, Conings R, Opdenakker G, Van Damme J: Identification of mouse granulocyte chemotactic protein-2 from fibroblasts and epithelial cells. Functional comparison with natural KC and macrophage inflammatory protein-2. J Immunol 1996;157:1736-1743.
14. Masure S, Paemen L, Proost P, Van Damme J, Opdenakker G: Expression of a human mutant monocyte chemotactic protein-3 (MCP-3) in Pichia pastoris and characterization as an MCP-3 receptor antagonist. J Interferon Cytokine Res 1995;15:955-963.
15. Proost P, De Meester I, Schols D, Struyf S, Lambeir AM, Wuyts A, Opdenakker G, De Clercq E, Scharpé S, Van Damme J: Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. J Biol Chem 1998;273:7222-7227.
16. Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, Boykens R, Unsworth E, Norcross MA: Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 1997;186:1865-1872.
17. Van Coillie E, Proost P, Van Aelst I, Struyf S, Polfliet M, De Meester I, Harvey DJ, Van Damme J, Opdenakker G: Functional comparison of two human monocyte chemotactic protein-2 isoforms. Role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV. Biochemistry 1998;37:12672-12680.
18. Uguccioni M, Loetscher P, Forssmann U, Dewald B, Li H, Hensche Lima S, Li Y, Kreider B, Carotta G, Thelen M, Baggiolini M: Monocyte chemotactic protein 4 (MCP-4), a novel structural and functional analogue of MCP-3 and eotaxin. J Exp Med 1996;183:2379-2384.
19. Struyf S, De Meester I, Scharpé S, Lenaerts J-P, Menten P, Wang JM, Proost P, Van Damme J: Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. Eur J Immunol 1998;28:1262-1271.
20. Schols D, Proost P, Struyf S, Wuyts A, De Meester I, Scharpé S, Van Damme J, De Clercq E: CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-I activity. Antivir Res 1998;39:175-187.
21. Proost P, Struyf S, Schols D, Durinx C, Wuyts A, Lenaerts JP, De Clereq E, De Meester I, Van Damme J: Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal cell-derived factor-1α. FEBS Lett 1998;432:73-76.
22. Ohtsuki T, Hosono O, Kobayashi H, Munakata Y, Souta A, Shioda T, Morimoto C: Negative regulation of the anti-human immunodeficiency virus and chemotactic activity of human stromal cell-derived factor 1α by CD26/dipeptidyl peptidase IV. FEBS Lett 1998;431:236-240.
23. Crump MP, Gong JH, Loetscher P, Rajarathnam K, Amara A, Arenzana-Seisdedos F, Virelizier JL, Baggiolini M, Sykes BD, dark-Lewis I: Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 1997;16:6996-7007.
24. Godiska R, Chantry D, Raport CJ, Sozzani S, Allavena P, Leviten D, Mantovani A, Gray PW: Human macrophage-derived chemokine (MDC), a novel chemoaltractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J Exp Med 1997;185:1595-1604.
25. Chang MS, McNinch J, Elias C III, Manthey CL, Grosshans D, Meng T, Boone T, Andrew DP: Molecular cloning and functional characterization of a novel CC chemokine, stimulated T cell chemotactic protein (STCP-1) that specifically acts on activated T lymphocytes. J Biol Chem 1997;272:25229-25237.
26. Pal R, Garzino-Demo A, Markham PD, Burns J, Brown M, Gallo RC, DeVico AL: Inhibition of HIV-1 infection by the β-chemokine MDC. Science 1997;278:695-698.
27. Proost P, Struyf S, Van Damme J, Opdenakker G, Sozzani S, Allavena P, Mantovani A, Augustijns K, Bal G, Haemers A, Lambeir AM, Scharpé S, De Meester I: Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 1999;274:3988-3993.
28. 2-terminally processed macrophage-derived chemokine imply an additional MDC receptor. J Immunol 1998;161:2672-1676.
29. Struyf S, Proost P, Schols D, De Clercq E, Opdenakker G, Lenaerts JP, Detheux M, Parmentier M, De Meester I, Scharpé S, Van Damme J: CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol 1999;162:4903-4909.
30. 4+ T cells expressing relatively high levels of CD26. Exp Cell Res 1998;241:352-362.